Amphix Bio is a preclinical stage company developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging. These therapies trigger targeted signaling pathways while forming scaffolds to support biological repair. Amphix Bio's goal is to increase human healthspan — the length of time that people can live productive, fulfilling lives.
Location: United States
Total raised: $12.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.12.2025 | Seed | $12.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 20.12.2025 | Amphix Bio Secures $12.5M to Propel Regenerative Peptide Therapies | Amphix Bio, a Chicago-based biotech firm, clinched $12.5 million in seed funding. This capital injection accelerates its cutting-edge peptide therapeutics toward critical human clinical trials. The company targets a spectrum of severe condi... |
| 19.12.2025 | Amphix Bio Raises $12.5M in Seed Funding | Amphix Bio, a Chicago, IL-based peptide therapeutics company for neurological injuries, raised $12.5M in Seed funding. Backers were not disclosed. The raise brought the total amount other than $18M. The company intends to use the funds to a... |
| 19.12.2025 | Sports Attack Receives Investment from Sound Growth Partners | Sports Attack, a Verdi, NV-based sports training equipments provider, received an investment from Sound Growth Partners. The amount of the deal was not disclosed. The company intends to use the funds to expand operations and its development... |
| 19.12.2025 | Amphix Bio: $12.5 Million Seed Funding Raised To Advance Peptide Therapeutics Toward Clinical Trials | Amphix Bio announced it has completed the initial closing of a $12.5 million seed financing round to move its lead therapeutic candidates toward human clinical trials and expand its pipeline into additional neurological conditions. The Chic... |
| 23.07.2025 | ‘Dancing Molecules’ Treatment Receives FDA Orphan Drug Designation | Regenerative spinal cord injury therapy repairs tissue, reverses paralysis in preclinical models A longitudinal spinal cord section treated with the most bioactive therapeutic scaffold. Regenerated axons (shown in red) regrew within the les... |
| - | Amphix Bio | “Amphix Bio is a preclinical stage company developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, dis... |